Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-182.15M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -34.65% |
| Return on Assets (Trailing 12 Months) | -32.76% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.36 |
| Quick Ratio (Most Recent Fiscal Quarter) | 16.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 46.11M |
| Free Float | 26.39M |
| Market Capitalization | $2.59B |
| Average Volume (Last 20 Days) | 0.93M |
| Beta (Past 60 Months) | 1.43 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 42.77% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.04% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |